Takahisa Furuta

Dr. Takahisa Furuta


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TFTakahisa Furuta
Takahisa Furuta
MYMihoko Yamade
Mihoko Yamade
THTomohiro Higuchi
Tomohiro Higuchi
TSTakahashi Satoru
Takahashi Satoru
NINatsuki Ishida
Natsuki Ishida
KSKEN SUGIMOTO
KEN SUGIMOTO
Vonoprazan (VPZ) inhibits gastric acid secretion more potently than proton pump inhibitors. Recently, attention has been focused on the dual therapy with VPZ and amoxicillin (AMOX) for the eradication of H. pylori. The dual VPZ/AMOX therapy attains the sufficient eradication rate with lowering the risk of adverse events in comparison with the triple therapy and quadruple therapy. Therefore, the dual VPZ/AMOX therapy is considered a useful eradication regimen for H. pylori infection.

12 April 2024 in Medicine
Verified
Journal Article
Open access
STSatoshi Tamura
Satoshi Tamura
YAYusuke Asai
Yusuke Asai
NINatsuki Ishida
Natsuki Ishida
TMTakahiro Miyazu
Takahiro Miyazu
STShinya Tani
Shinya Tani
KSKEN SUGIMOTO
KEN SUGIMOTO
Ustekinumab is prescribed for the treatment of patients with steroid-resistant moderate to severe Crohn’s disease. We investigated its clinical outcome in patients with small and large intestinal lesions. Patients who were newly administered ustekinumab between March 2014 and December 2020 at Hamamatsu University Hospital were included in the study. The primary endpoint was Crohn’s disease activity index score at baseline and weeks 8, 24, and 48 after the initiation of treatment, and secondary endpoints were albumin, hemoglobin, and C-reactive protein at these time points. Ustekinumab treatment retention was examined in both groups; the 2 groups were compared using the Friedman test, Mann–Whitney U test, or Fisher exact test. Overall, Crohn’s disease activity index scores improved between baseline and 48 weeks, but the difference was not significant. However, there was a significant improvement between baseline and 48 weeks in patients with lesions in the small intestine only. Overall, patients showed significant improvement in albumin levels between baseline and 48 weeks but not in C-reactive protein or hemoglobin levels. When limited to patients with lesions in the small intestine, albumin and hemoglobin levels showed significant improvement. Both types showed high rates of treatment retention, although there was no significant difference. Ustekinumab appears to be a safe and effective treatment option that may be particularly effective in patients with lesions in the small intestine only.